Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE +0.00%, DAX +0.05%, CAC40 +0.06%

Dec 09 ,2025

  • Synopsis

    • European equity indices are set to open little changed at this time, amidst mostly lower trading in Asia with US futures mostly unchanged. US equities finished lower in Monday trading, ending not far from worst levels. US dollar unchanged, AUD higher on RBA's 'hawkish hold', NZD also stronger, quiet elsewhere. Treasury yields mostly higher, JGBs mixed. Crude lower, precious metals mixed. Iron ore at its lowest level in four weeks ahead of key government strategy meetings in Beijing this week. Cryptocurrencies weaker with bitcoin back below $90K.

    • Rate backup remains one of the bigger stories as a hawkish cut has become the consensus for Wednesday's FOMC. Treasury market also dealing with more supply this week, global central banks have recently tilted more hawkish and more talk of "run it hot" trade. Of note, RBA left cash rate unchanged at 3.60% as expected. Decision was unanimous and board judged it appropriate to remain cautious. In other news, Ukraine is preparing to present a revised peace plan to the White House and Zelensky rules out giving up land.

    • On the agenda for today, Siemens (SIE.GR) hosts CMD today and Anglo American (AAL.LN) and Teck Resources (TECK.B.CN) host a merger call.

    • UK Worldpanel by Numerator (formerly Kantar's Worldpanel division) releases grocery market share figures. Amidst light macroeconomic data, Germany Oct Trade Balance and Norway Nov PPI are due at 7:00 GMT, followed by Greece Nov CPI at 10:00 GMT.

  • Politics/Macro/World News

    • Ukraine to share revised peace plan with US on Tuesday, Zelenskiy says - Reuters

    • French premier faces razor-edge vote on welfare financing - FT

    • ECB Renews Request for Italy to Reconsider Gold Reserves Plan - Bloomberg

    • UK Nov retail sales +1.2% y/y vs consensus +2.4% and prior +1.5% - BRC

    • Netherlands Nov CPI +2.9% y/y vs preliminary +2.9%

  • Top company news

    • Earnings/updates

      • TKA.GR (ThyssenKrupp) -- FY EPS €0.75 vs consensus €0.27; expects FY25/26 adj EBIT between €500-900M

      • OCI.NA (OCI NV) -- OCI Global Q3 trading update: cont ops maintained profitability

      • MRX.GR (Mister Spex) -- Black Friday 2025 performance: +16% store revenue growth y/y

      • SYDB.DC (Sydbank) -- selects Bankdata as future provider of IT solutions for AL Sydbank; consequently will exit BEC with related exit fee impacting 2025 guidance

      • RUSTA.SS (Rusta) -- Q2 EPS SEK0.7 vs FactSet SEK0.46 [3 est, SEK0.43-0.49]

    • M&A

      • OCI.NA (OCI NV) -- Orascom Construction to buy OCI Global for shares

      • SPIE.FP (SPIE) -- acquires Cyqueo in Germany

      • DKSH.SW (DKSH Holding) -- to buy remaining 25.7% of its Malaysian subsidiary; aims to delist the company from the Malaysian Stock Exchange

      • CEP (Twenty One) -- Capital completes business combination with Cantor Equity Partners

      • INWI.SS (Inwido) -- acquires Victorian House Window Group for £60M

      • VMX.FP (Verimatrix) -- agrees to sell XTD assets to Guardsquare for an initial ~ $8.5M

      • EU clears Warburg Pincus' acquisition of Sebia

    • Healthcare

      • ROG.SW (Roche) -- launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

      • ROG.SW (Roche Holding) -- Genentech presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

      • ROG.SW (Roche Holding) -- European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis

      • SN.LN (Smith & Nephew) -- Transcript Intelligence: Smith & Nephew Capital Markets Day

      • GMAB.DC (Genmab) -- reports data from Phase 1b/2 EPCORE CLL-1 trial evaluating epcoritamab-bysp as monotherapy and in combination for treatment of RT

      • OSE.FP (OSE Immunotherapeutics) -- unveils 2026-2028 Strategic Plan With Four Opportunities for Value Creation

      • 4523.JP (Eisai) -- Eisai, Biogen's anti-Aß protofibril antibody LEQEMBI included in National Reimbursement Drug List

    • Other

      • RNO.FP (Renault) , F (Ford) -- sign partnership agreement to develop two Ford-branded passenger electric vehicles and sign LOI for a European light commercial vehicle collaboration

      • EVT.GR Novo Holdings selling up to ~9.4M shares in Evotec -- wires (8-Dec, post European market close)

      • ULVR.LN (Unilever) -- share consolidation ratio set at 8 new shares for every 9 existing shares (12:51 ET/17:51 GMT/18:51 CET)

      • SKA.B.SS (Skanska) -- signs additional contract with an existing client for data center in Virginia, US, for $105M, ~ SEK 1B

      • VOW3.GR (Volkswagen) -- Piëch family reliant on steady dividends from Volkswagen amid debt repayment obligations - Bloomberg

      • ENR.GR (Siemens Energy) -- Activist Engine Capital builds stake in Siemens Energy; presses company to spin off wind business - FT

      • NDX1.GR (Nordex Group) -- wins orders for 102 MW in France and Belgium

      • ASM.NA (ASM International) -- intends to reappoint Hichem M'Saad for second term, for four years, as member of the Management board and as CEO

      • LAGR.B.SS (Lagercrantz Group) -- appoints Karin Mellegård Djärf as CFO

      • ARB.LN (Argo Blockchain) -- provides update on court sanction hearing

  • Key rating changes

    • Upgrades

      • EMG.LN (Man Group) -- to overweight from neutral at JPMorgan

      • EQT.SS (EQT AB) -- to overweight from neutral at JPMorgan

      • ETE.GA (National Bank of Greece) -- to outperform from neutral at Autonomous Research

      • RBI.AV (Raiffeisen Bank International) -- to outperform from neutral at Autonomous Research

      • ALV.GR (Allianz) -- to outperform from market perform at Keefe, Bruyette & Woods

      • G.IM (Assicurazioni Generali) -- to outperform from market perform at Keefe, Bruyette & Woods

      • BIRG.ID (Bank of Ireland Group) -- to outperform from neutral at Mediobanca

      • RED.SM (Redeia Corporacion) -- to outperform from market perform at Bernstein

      • REL.LN (RELX) -- to buy from hold at Deutsche Numis

      • EPI.A.SS (Epiroc) -- to outperform from neutral at BNP Paribas Exane

      • WKL.NA (Wolters Kluwer) -- to buy from hold at Deutsche Bank

    • Downgrades

      • HFG.GR (HelloFresh) -- to underweight from equal-weight at Morgan Stanley

      • SREN.SW (Swiss Re) -- to hold from buy at Berenberg

    • Initiantions

      • ROSE.LN (Rosebank Industries) -- buy at Berenberg

      • MICC.NA (The Magnum Ice Cream Co. N.V.) -- buy at UBS

      • HBAN.SW (Helvetia Baloise Holding) -- outperform at Autonomous Research

      • BILI.A.SS (Bilia) -- buy at Handelsbanken

      • FLS.DC (FLSmidth & Co.) -- neutral at UBS

      • RTO.LN (Rentokil Initial) -- buy at Kepler Cheuvreux

  • Data

    • Nikkei +0.14% to 50655.10

    • Hang Seng (1.27%) to 25438.48

    • Shanghai Composite (0.42%) to 3907.48

    • S&P futures +5.8 vs prior close of 6855.8

    • €-$ +0.0005 or +0.04% to 1.1644

    • $-¥ +0.10 or +0.06% to 156.02

    • €-¥ +0.20 or +0.11% to 181.66

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE